Heterogeneity of HER2 Expression in Circulating Tumor Cells of Patients with Breast Cancer Brain Metastases and Impact on Brain Disease Control

HER2 expression switching in circulating tumor cells (CTC) in breast cancer is dynamic and may have prognostic and predictive clinical implications. In this study, we evaluated the association between the expression of HER2 in the CTC of patients with breast cancer brain metastases (BCBM) and brain...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-06, Vol.14 (13), p.3101
Main Authors: de Castro, Douglas Guedes, Pellizzon, Antônio Cássio Assis, Braun, Alexcia Camila, Chen, Michael Jenwei, Silva, Maria Letícia Gobo, Fogaroli, Ricardo Cesar, Gondim, Guilherme Rocha Melo, Ramos, Henderson, Neto, Elson Santos, Abrahão, Carolina Humeres, Yu, Liao Shin, Abdallah, Emne Ali, Calsavara, Vinicius Fernando, Chinen, Ludmilla Thomé Domingos
Format: Article
Language:English
Subjects:
Antibodies
Brain diseases
Breast cancer
Disease control
ErbB-2 protein
Magnetic resonance imaging
Medical prognosis
Membranes
Metastases
Metastasis
Multivariate analysis
Patients
Radiation therapy
Radiosurgery
Statistical analysis
Survival analysis
Tumor cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HER2 expression switching in circulating tumor cells (CTC) in breast cancer is dynamic and may have prognostic and predictive clinical implications. In this study, we evaluated the association between the expression of HER2 in the CTC of patients with breast cancer brain metastases (BCBM) and brain disease control. An exploratory analysis of a prospective assessment of CTC before (CTC1) and after (CTC2) stereotactic radiotherapy/radiosurgery (SRT) for BCBM in 39 women was performed. Distant brain failure-free survival (DBFFS), the primary endpoint, and overall survival (OS) were estimated. After a median follow-up of 16.6 months, there were 15 patients with distant brain failure and 16 deaths. The median DBFFS and OS were 15.3 and 19.5 months, respectively. The median DBFFS was 10 months in patients without HER2 expressed in CTC and was not reached in patients with HER2 in CTC (p = 0.012). The median OS was 17 months in patients without HER2 in CTC and was not reached in patients with HER2 in CTC (p = 0.104). On the multivariate analysis, DBFFS was superior in patients who were primary immunophenotype (PIP) HER2-positive (HR 0.128, 95% CI 0.025–0.534; p = 0.013). The expression of HER2 in CTC was associated with a longer DBFFS, and the switching of HER2 expression between the PIP and CTC may have an impact on prognosis and treatment selection for BCBM.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14133101